Prostatype Genomics マネジメント

マネジメント基準チェック /14

Prostatype Genomicsの CEO はFredrik Rickmanで、 Jan2017年に任命され、の在任期間は 7.83年です。は、会社の株式の0.018%を直接所有しており、その価値はSEK 1.43K 。経営陣と取締役会の平均在任期間はそれぞれ1.9年と4.1年です。

主要情報

Fredrik Rickman

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	7.8yrs
CEOの所有権	0.02%
経営陣の平均在職期間	1.9yrs
取締役会の平均在任期間	4.1yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Fredrik Rickman

7.8yrs

在職期間

Mr. Fredrik Rickman (Previously Fredrik Rickman) has been Chief Executive Officer of Prostatype Genomics AB (publ) since 2017 and serves as its Managing Director. He has years of international life science...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Fredrik Rickman	CEO & MD	7.8yrs	データなし	0.018% SEK 1.4k
Anders Koch	Chief Financial Officer	1.1yrs	データなし	データなし
George Skinner	Vice President Commercial operations	no data	データなし	データなし
Emelie Berglund	Chief Technology Officer	2yrs	データなし	0.0011% SEK 90.2
Nicklas Rosendal	Communications Director	3.2yrs	データなし	データなし
Joakim Soderin	Chief Auditor	2.4yrs	データなし	データなし
Gerald Andriole	Global Chief Medical Officer	1.5yrs	データなし	データなし
Steven Gaal	President US operations	1.8yrs	データなし	データなし
Katarina Sjöberg	QA & RA Manager	1.8yrs	データなし	データなし
Mats Bergström	Sales Director of EMEA	no data	データなし	データなし

1.9yrs

平均在職期間

経験豊富な経営陣: PROGENの経営陣は経験豊富とはみなされません ( 1.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Anders Lundberg	Independent Chairman of the Board	7.8yrs	データなし	データなし
Mattias Prage	Independent Director	2.4yrs	データなし	データなし
Hakan Englund	Independent Director	5.8yrs	データなし	0.85% SEK 69.4k
Michael Haggman	Independent Director	6.8yrs	データなし	7.49% SEK 608.4k
Rolf Skoglund	Member of Advisory Board	no data	データなし	データなし
Jörgen Dahlström	Independent Director	less than a year	データなし	0.010% SEK 819.8
Johan Waldhe	Director	less than a year	データなし	データなし

4.1yrs

平均在職期間

経験豊富なボード: PROGENの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

Prostatype Genomics マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Independent Director recently bought kr821k worth of stock

Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the Board

Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely

Prostatype Genomics Appoints Anders Koch as New CFO

Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company

Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer

Recent updates

Independent Director recently bought kr821k worth of stock

Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million.

First half 2024 earnings released: kr0.031 loss per share (vs kr0.37 loss in 1H 2023)

Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the Board

Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala

Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®

Prostatype Genomics AB (publ) to Report Fiscal Year 2024 Results on Feb 13, 2025

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Prostatype Genomics AB (publ) Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®

Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely

Prostatype Genomics Appoints Anders Koch as New CFO

Prostatype Genomics AB (Publ) Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype Genomics

Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)

New major risk - Share price stability

Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company

Second quarter 2023 earnings: Revenues miss analyst expectations

Prostatype Genomics AB (Publ) Provides Revenue Guidance for the Third Quarter of 2023

Now 26% undervalued after recent price drop

Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer

First quarter 2023 earnings released

Prostatype Genomics AB (Publ) Announces Executive Changes

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB Appoints Professor Gerald Andriole as Chief Medical Officer

Full year 2022 earnings released: kr1.27 loss per share (vs kr1.11 loss in FY 2021)

Prostatype Genomics AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023

Prostatype Genomics AB (publ) to Report Q2, 2023 Results on Aug 17, 2023

Prostatype Genomics Appoints Steven Gaal as President

Prostatype Genomics AB (Publ) Provides Sales Guidance for the Year 2022

Prostatype Genomics Announces Management Changes

Prostatype Shows Strong Data in Asian Pilot Study

Second quarter 2022 earnings released

High number of new directors

Prostatype Genomics AB (Publ) Appoints Mattias Prage as Member of the Board

First quarter 2022 earnings released

Insufficient new directors

Prostatype Genomics AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

CEO & MD recently bought kr72k worth of stock

Insider recently bought kr108k worth of stock

Third quarter 2021 earnings released

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.724583 million.

Second quarter 2021 earnings released: kr0.18 loss per share (vs kr0.42 loss in 2Q 2020)

Prostatype Genomics AB (publ) to Report Q4, 2020 Results on May 17, 2021

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /14